![\"Banner](\"https://www.artificialintelligence-news.com/wp-content/uploads/2026/05/image.png\")
Takeda has entered a strategic collaboration with Hong Kong-based Insilico Medicine to use AI in early-stage drug discovery across the Japanese pharmaceutical company’s therapeutic areas. The companies did not disclose which therapeutic areas or disease targets will be covered under the collaboration. The agreement gives Takeda access to Insilico’s Pharma.AI platform, which supports biological target […]
\nThe post Takeda signs US$600M AI drug discovery deal with Insilico appeared first on AI News.
", "content_html": "Takeda has entered a strategic collaboration with Hong Kong-based Insilico Medicine to use AI in early-stage drug discovery across the Japanese pharmaceutical company’s therapeutic areas.
\n\n\n\nThe companies did not disclose which therapeutic areas or disease targets will be covered under the collaboration. The agreement gives Takeda access to Insilico’s Pharma.AI platform, which supports biological target identification, molecular design, and clinical trial prediction.
\n\n\n\nThe companies said the collaboration will focus on identifying drug candidates that meet predefined scientific and early development criteria. Insilico will lead the AI-driven discovery work, while Takeda will take responsibility for advancing selected candidates through clinical development.
\n\n\n\nTakeda will receive exclusive worldwide rights to develop, manufacture, and commercialise novel therapeutics selected through the collaboration.
\n\n\n\nInsilico said the deal includes about US$60 million in project initiation fees, near-term payments, and milestones. The total value could reach about US$600 million if preclinical, clinical, commercial, and sales milestones are achieved.
\n\n\n\nAdditional payments are tied to preclinical, clinical, commercial, and sales milestones. Insilico is also eligible to receive tiered royalties on future sales.
\n\n\n\nInsilico founder and CEO Alex Zhavoronkov said proceeds from the deal will support early-stage research and development under the collaboration program. Zhavoronkov also said later-stage timelines will depend on Takeda’s clinical development activities and the coordinated work of both companies.
\n\n\n\nThe Pharma.AI suite includes tools used for target discovery, molecule generation, and clinical development prediction. Published descriptions of the platform identify PandaOmics for target discovery, Chemistry42 for de novo small-molecule generation, and InClinico for forecasting clinical trial transition probability.
\n\n\n\nInsilico has also advanced its own AI-generated drug candidate into clinical testing. Rentosertib, formerly known as ISM001-055 or INS018_055, is a small-molecule TNIK inhibitor for idiopathic pulmonary fibrosis that was evaluated in a Phase 2a randomised clinical trial.
\n\n\n\nChris Arendt, chief scientific officer and head of research at Takeda, said the agreement combines Takeda’s disease biology work with Insilico’s AI-enabled discovery capabilities. He said Takeda is also integrating automation, robotics, and generative AI into its discovery work.
\n\n\n\nThe Insilico agreement follows another AI drug-discovery deal by Takeda earlier this year. In February, Takeda entered a multi-year collaboration with Iambic worth more than US$1.7 billion to use AI in the design of small-molecule drugs for cancer and gastrointestinal diseases.
\n\n\n\nIambic’s platform includes NeuralPLexer, an AI model used to predict how drug molecules bind to proteins.
\n\n\n\nChinese drugmakers signed 157 out-licensing deals worth US$135.7 billion in 2025, according to data cited by the South China Morning Post from China’s National Medical Products Administration.
\n\n\n\nIn the Takeda–Insilico agreement, Takeda receives exclusive worldwide rights to candidates discovered through Insilico’s platform. Insilico said it has signed collaboration agreements with a combined potential value of more than US$7 billion since the start of the year.
\n\n\n\nLast month, Insilico announced a collaboration with South Korea’s SK Biopharmaceuticals focused on neuroimmune disorders. That agreement includes up to US$18 million in upfront and near-term milestone payments, with a total potential value of more than US$2.5 billion.
\n\n\n\nIn March, Eli Lilly expanded its collaboration with Insilico in an AI-powered drug discovery deal worth up to US$2.75 billion. The agreement gave Lilly exclusive worldwide rights to develop, manufacture, and commercialise certain oral treatments then in preclinical development.
\n\n\n\nInsilico’s Hong Kong-listed shares rose 13.5% after the Takeda agreement was announced.
\n\n\n\n(Photo by Serkan Yildiz)
\n\n\n\nSee also: NVIDIA BioNeMo accelerates Anthropic Claude Science
\n\n\n\nWant to learn more about AI and big data from industry leaders? Check out AI & Big Data Expo taking place in Amsterdam, California, and London. The comprehensive event is part of TechEx and is co-located with other leading technology events including the Cyber Security & Cloud Expo. Click here for more information.
\n\n\n\nAI News is powered by TechForge Media. Explore other upcoming enterprise technology events and webinars here.
\nThe post Takeda signs US$600M AI drug discovery deal with Insilico appeared first on AI News.
", "content_text": "Takeda has entered a strategic collaboration with Hong Kong-based Insilico Medicine to use AI in early-stage drug discovery across the Japanese pharmaceutical company’s therapeutic areas.\nThe companies did not disclose which therapeutic areas or disease targets will be covered under the collaboration. The agreement gives Takeda access to Insilico’s Pharma.AI platform, which supports biological target identification, molecular design, and clinical trial prediction.\nThe companies said the collaboration will focus on identifying drug candidates that meet predefined scientific and early development criteria. Insilico will lead the AI-driven discovery work, while Takeda will take responsibility for advancing selected candidates through clinical development.\nDeal value and development rights\nTakeda will receive exclusive worldwide rights to develop, manufacture, and commercialise novel therapeutics selected through the collaboration.\nInsilico said the deal includes about US$60 million in project initiation fees, near-term payments, and milestones. The total value could reach about US$600 million if preclinical, clinical, commercial, and sales milestones are achieved.\nAdditional payments are tied to preclinical, clinical, commercial, and sales milestones. Insilico is also eligible to receive tiered royalties on future sales.\nInsilico founder and CEO Alex Zhavoronkov said proceeds from the deal will support early-stage research and development under the collaboration program. Zhavoronkov also said later-stage timelines will depend on Takeda’s clinical development activities and the coordinated work of both companies.\nAI drug discovery partnerships\nThe Pharma.AI suite includes tools used for target discovery, molecule generation, and clinical development prediction. Published descriptions of the platform identify PandaOmics for target discovery, Chemistry42 for de novo small-molecule generation, and InClinico for forecasting clinical trial transition probability.\nInsilico has also advanced its own AI-generated drug candidate into clinical testing. Rentosertib, formerly known as ISM001-055 or INS018_055, is a small-molecule TNIK inhibitor for idiopathic pulmonary fibrosis that was evaluated in a Phase 2a randomised clinical trial.\nChris Arendt, chief scientific officer and head of research at Takeda, said the agreement combines Takeda’s disease biology work with Insilico’s AI-enabled discovery capabilities. He said Takeda is also integrating automation, robotics, and generative AI into its discovery work.\nThe Insilico agreement follows another AI drug-discovery deal by Takeda earlier this year. In February, Takeda entered a multi-year collaboration with Iambic worth more than US$1.7 billion to use AI in the design of small-molecule drugs for cancer and gastrointestinal diseases.\nIambic’s platform includes NeuralPLexer, an AI model used to predict how drug molecules bind to proteins.\nChinese drugmakers signed 157 out-licensing deals worth US$135.7 billion in 2025, according to data cited by the South China Morning Post from China’s National Medical Products Administration.\nIn the Takeda–Insilico agreement, Takeda receives exclusive worldwide rights to candidates discovered through Insilico’s platform. Insilico said it has signed collaboration agreements with a combined potential value of more than US$7 billion since the start of the year.\nLast month, Insilico announced a collaboration with South Korea’s SK Biopharmaceuticals focused on neuroimmune disorders. That agreement includes up to US$18 million in upfront and near-term milestone payments, with a total potential value of more than US$2.5 billion.\nIn March, Eli Lilly expanded its collaboration with Insilico in an AI-powered drug discovery deal worth up to US$2.75 billion. The agreement gave Lilly exclusive worldwide rights to develop, manufacture, and commercialise certain oral treatments then in preclinical development.\nInsilico’s Hong Kong-listed shares rose 13.5% after the Takeda agreement was announced.\n(Photo by\nSerkan Yildiz\n)\nSee also:\nNVIDIA BioNeMo accelerates Anthropic Claude Science\nWant to learn more about AI and big data from industry leaders?\nCheck out\nAI & Big Data Expo\ntaking place in Amsterdam, California, and London. The comprehensive event is part of\nTechEx\nand is co-located with other leading technology events including the\nCyber Security & Cloud Expo\n. Click\nhere\nfor more information.\nAI News is powered by\nTechForge Media\n. Explore other upcoming enterprise technology events and webinars\nhere\n.\nThe post\nTakeda signs US$600M AI drug discovery deal with Insilico\nappeared first on\nAI News\n.", "image": { "url": "https://virtues.guru/tech-assets/53_The_relationship_and_main_types_of_artificial_intelligence_machine_learning_and_deep_learning.webp", "file": "53_The_relationship_and_main_types_of_artificial_intelligence_machine_learning_and_deep_learning.webp", "title": "File:The relationship and main types of artificial intelligence, machine learning and deep learning.webp" }, "language": "en", "translations": { "pt": { "title": "Takeda assina acordo de descoberta de medicamentos por IA no valor de US$ 600 milhões com a Insilico", "content_text": "A Takeda se associou à Insilico Medicine para utilizar a inteligência artificial na descoberta de medicamentos em fase inicial. O acordo concede à Takeda acesso à plataforma Pharma.AI da Insilico, que suporta a identificação de alvos biológicos, o design molecular e a previsão de ensaios clínicos. A colaboração se concentrará na identificação de candidatos a medicamentos que atendam a critérios científicos e de desenvolvimento definidos. A Takeda receberá direitos exclusivos em todo o mundo para desenvolver, fabricar e comercializar novos medicamentos selecionados através da colaboração. O valor do acordo pode chegar a US$ 600 milhões.", "summary_en": "Takeda has partnered with Insilico Medicine to use AI in early-stage drug discovery. The deal gives Takeda access to Insilico's Pharma.AI platform, which supports biological target identification, molecular design, and clinical trial prediction. The collaboration will focus on identifying drug candidates that meet predefined scientific and early development criteria. Takeda will receive exclusive worldwide rights to develop, manufacture, and commercialise novel therapeutics selected through the collaboration. The deal is worth up to US$600 million.", "translated_at": "2026-07-06T06:22:45.829180+00:00", "model": "translategemma:4b", "summary_model": "llama3.1:8b", "source": "json_summary" } } }